Background & Aims: The molecular mechanism of action of the Janus kinase (JAK) inhibitor tofacitinib is poorly understood.
Methods: Here, we analysed the inhibitory effect of tofacitinib on mucosal and blood T cells from patients with ulcerative colitis (UC). Furthermore tofacitinib treatment was analysed in experimental colitis models and wound healing.